Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages

References

• Feasey N, Wansbrough-Jones M, Mabey DCW, et al. Neglected tropical diseases. Br Med Bull. 2010;93(1):179–200.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO, Neglected tropical diseases: treating more than one billion people in 2017 [Internet]. Who. 2018 [cited 2001 Sep 20]. Available from: https://www.who.int/neglected_diseases/news/treating-more-than-one-billion-people-2017/en/
   Google Scholar
• WHO/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases, Third WHO report on neglected tropical diseases [Internet]. 2015. Available from:https://www.who.int/neglected_diseases/9789241564861/en/
   Google Scholar
• World Health Organization (WHO). Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases [Internet]. Geneva (Switzerland); 2017. Available from: https://apps.who.int/iris/handle/10665/255011
   Google Scholar
• WHO. Neglected tropical diseases [Internet]. 2019. [2019 Nov 13]. Available from: https://www.who.int/neglected_diseases/diseases/en/
   Google Scholar
• END Fund. End fund Nigeria [Internet]. [cited 2021 Apr 06]. Available from: http://www.end.org/ourimpact/wherewework/nigeria
   Google Scholar
• Yamey G. The world’s most neglected diseases. Br Med J. 2002;325(7357):176–177.
   PubMedGoogle Scholar
• Lee BY, Bartsch SM, Gorham KM. Economic and financial evaluation of neglected tropical diseases. In: Anderson RM, Basáñez MG, editors. Advances in Parasitology, Advances in Parasitology, Vol. 87. Cambridge, Massachusetts, EUA: Academic Press; 2015. 329–417.
   Google Scholar
• The World Bank. Poverty [Internet]. [cited 2021 Mar 18]. Available from: https://data.worldbank.org/topic/11
   Google Scholar
• Comissão Econômica para a América Latina e o Caribe (CEPAL). Panorama Social da América Latina, 2019. In: Resumo executivo (LC/PUB.2020/1-P). Santiago: Publicação das Nações Unidas; 2020: 1–16.
   Google Scholar
• General Assembly. Transforming our world: the 2030 agenda for sustainable development, A/RES/70/1 [Internet]. A New Era in Global Health. 2015. [cited 2021 Apr 06]. Available from: https://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E
   Google Scholar
• United Nations. Sustainable Development Goals [Internet]. [cited 2021 Mar 18]. Available from: https://sdgs.un.org/goals
   Google Scholar
• WHO/Department of control of neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases, First WHO report on neglected tropical diseases [Internet]. 2010. [cited 2021 Apr 06]. Available from: https://www.who.int/neglected_diseases/resources/9789241564090/en/
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Alvarado M, Basáñez MG, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8(7):7.
   Web of Science ®Google Scholar
• Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. brooker S, editor. PLoS Negl Trop Dis. 2007;1(2):e114.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Global Health Data Exchange [Internet]. [cited 2021 Jul 13]. Available from: http://ghdx.healthdata.org/
   Google Scholar
• Organización Panamericana de la Salud. Más de 100 millones de personas padecen alguna enfermedad infecciosa desatendida en las Américas [Internet]. 2015 [2001 Sep 20]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=10440%3A2015-100-millones-padecen-alguna-enfermedad-infecciosa-desatendida-en-las-americas&catid=740%3Anews-press-releases&Itemid=1926&lang=es
   Google Scholar
• World Health Organization (WHO). Schistosomiasis [Internet]. 2020 [2021 Jan 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
   Google Scholar
• World Health Organization (WHO). Schistosomiasis (Bilharzia) [Internet]. [cited 2021 Jan 27]. Available from: https://www.who.int/health-topics/schistosomiasis#tab=tab_1
   Google Scholar
• Da Silva LC, Chieffi PP, Carrilho FJ. Schistosomiasis mansoni – clinical features. Gastroenterol Hepatol. 2005;28(1):30–39.
   PubMedGoogle Scholar
• Lambertucci JR. Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools. Rev Soc Bras Med Trop. 2014;47(2):130–136.
   PubMed Web of Science ®Google Scholar
• Ferrari TCA, Moreira PRR. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol. 2011;10(9):853–864.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Model List of Essential Medicines, 20th List [Internet]. Geneva; 2019. [cited 2021 Apr 06]. Available from: https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
   Google Scholar
• History of Praziquantel [Internet]. [cited 2021 Mar 18]. Available from: https://web.stanford.edu/group/parasites/ParaSites2006/Praziquantel/history.html
   Google Scholar
• Xu J, Bergquist R, Qian Y-J, et al. China–Africa and China–Asia collaboration on schistosomiasis control. In 2016. p. 435–466.
   Google Scholar
• Song L-G, Wu X-Y, Sacko M, et al. History of schistosomiasis epidemiology, current status, and challenges in China: on the road to schistosomiasis elimination. Parasitol Res. 2016;115(11):4071–4081.
   PubMed Web of Science ®Google Scholar
• Chen MG. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience. Acta Trop. 2005;96(2–3):168–176.
   PubMed Web of Science ®Google Scholar
• Secor WE. Early lessons from schistosomiasis mass drug administration programs. F1000Research 2015;4:1157.
   Google Scholar
• L-a TT, Rollinson D, Stothard JR, et al. Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. Infect Dis Poverty. 2017;6(1):42.
   PubMedGoogle Scholar
• Ndeffo Mbah ML, Gilbert JA, Galvani AP. Evaluating the potential impact of mass praziquantel administration for HIV prevention in Schistosoma haematobium high-risk communities. Epidemics 2014;7:22–27.
   PubMed Web of Science ®Google Scholar
• Randjelovic A, Frønæs S, Munsami M, et al. A study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa. South Afr Fam Pract. 2015;57(2):57–61.
   Web of Science ®Google Scholar
• Onkanga IO, Mwinzi PNM, Muchiri G, et al. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol. 2016;46(7):439–445.
   PubMed Web of Science ®Google Scholar
• Dias JP, Bastos C, Araújo E, et al. Acute Chagas disease outbreak associated with oral transmission. Rev Soc Bras Med Trop. 2008;41(3):296–300.
   PubMed Web of Science ®Google Scholar
• CAC A, Waniek PJ, Jansen AM. An overview of chagas disease and the role of triatomines on its distribution in Brazil. Vector-Borne Zoonotic Dis. 2009;9(3):227–234.
   PubMed Web of Science ®Google Scholar
• Valente SADS, Valente VDC, Fraiha Neto H. Considerations on the epidemiology and transmission of Chagas disease in the Brazilian amazon. Mem Inst Oswaldo Cruz. 1999;94(suppl 1):395–398.
   Google Scholar
• Souza-Lima RDCD, Barbosa MDGV, Coura JR, et al. Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon. Rev Soc Bras Med Trop. 2013;46(4):510–514.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Chagas disease (American trypanosomiasis) [Internet]. [cited 2021 Jan 27]. Available from: https://www.who.int/chagas/epidemiology/en/
   Google Scholar
• Bern C, Messenger LA, Whitman JD, et al. Chagas disease in the united states: a public health approach. Clin Microbiol Rev. 2019;33:1.
   Web of Science ®Google Scholar
• Conners EE, Vinetz JM, Weeks JR, et al. A global systematic review of Chagas disease prevalence among migrants. Acta Trop. 2016;156:68–78.
   PubMed Web of Science ®Google Scholar
• Manne-Goehler J, Umeh CA, Montgomery SP, et al. Estimating the Burden of Chagas Disease in the United States. Dumonteil E, editor. PLoS Negl Trop Dis. 2016;10(11):e0005033.
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, Aldasoro E, De Lazzari E, et al. Prevalence of chagas disease in latin-american migrants living in europe: a systematic review and meta-analysis. Rodrigues MM, editor. PLoS Negl Trop Dis. 2015;9(2):e0003540.
   PubMed Web of Science ®Google Scholar
• Antinori S, Galimberti L, Bianco R, et al. Chagas disease in Europe: a review for the internist in the globalized world. Eur J Intern Med. 2017;43:6–15.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO. Chagas disease (American trypanosomiasis) [Internet]. 2020 [2021 Jan 27]. Available from: https://www.who.int/health-topics/chagas-disease#tab=tab_1
   Google Scholar
• Martins-Melo FR, Carneiro M, Ribeiro ALP, et al. Burden of Chagas disease in Brazil, 1990–2016: findings from the Global Burden of Disease Study 2016. Int J Parasitol. 2019;49(3–4):301–310.
   PubMed Web of Science ®Google Scholar
• Coura JR. Chagas disease: what is known and what is needed - A background article. Mem Inst Oswaldo Cruz. 2007;102(suppl 1):113–122.
   PubMedGoogle Scholar
• Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159–218.
   Google Scholar
• Caldas IS, Talvani A, Caldas S, et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res. 2008;103(2):413–421.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Perez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64(6):1139–1147.
   PubMed Web of Science ®Google Scholar
• Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44(1):29–37.
   PubMedGoogle Scholar
• Simões MV, Romano MMD, Schmidt A, et al. Chagas Disease Cardiomyopathy. Int J Cardiovasc Sci. 2018;31:2.
   Google Scholar
• Jr AR, Rassi A, Little WC. Chagas’ Heart Disease. Clin Cardiol. 2000;23(12):883–889.
   PubMed Web of Science ®Google Scholar
• Punukollu G, Gowda RM, Khan IA, et al. Clinical aspects of the Chagas’ heart disease. Int J Cardiol. 2007;115(3):279–283.
   PubMed Web of Science ®Google Scholar
• Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106(6):641–645.
   PubMed Web of Science ®Google Scholar
• Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1(2):92–100.
   PubMedGoogle Scholar
• Gullo CE, Estofolete CF, Gil CD, et al. Formas digestivas da doença de Chagas e carcinogênese: um estudo de associação. Rev Col Bras Cir. 2012;39(2):146–150.
   PubMedGoogle Scholar
• Matsuda NM, Miller SM, Evora PRB. The chronic gastrointestinal manifestations of Chagas disease. Clinics. 2009;64(12):1219–1224.
   PubMed Web of Science ®Google Scholar
• Rocha A, Henrique D, Borges E, et al. Complicacoes do megacolon e megaesofago chagasicos observadas em necropsia. Rev Goiana Med. 1981;27(1/2):53–62.
   Google Scholar
• Rossi A, Rezende JMD, Doles J. Caso de Doença de Chagas observado desde o período inicial da infecção, com aparecimento precoce de magaesôfago e megacolo. Rev Soc Bras Med Trop. 1968;2(6):303–315.
   Google Scholar
• Figueirêdo SDS, Carvalho TN, Nóbrega BBD, et al. Caracterização radiográfica das manifestações esofagogastrointestinais da doença de Chagas. Radiol Bras. 2002;35(5):293–297.
   Google Scholar
• de Oliveira R. Gastrointestinal manifestations of chagas’ disease. Am J Gastroenterol. 1998;93(6):884–889.
   PubMed Web of Science ®Google Scholar
• Abuhab A, Trindade E, Aulicino GB, et al. Chagas’ cardiomyopathy: the economic burden of an expensive and neglected disease. Int J Cardiol. 2013;168(3):2375–2380.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO. Chagas disease (also known as American trypanosomiasis) [Internet]. 2020 [2021 Feb 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
   Google Scholar
• LAFEPE. Guia de Compras do Benznidazol [Internet]. [cited 2021 Mar 17]. Available from: https://www.lafepe.pe.gov.br/
   Google Scholar
• DNDi. Paediatric Benznidazole [Internet]. [cited 2021 Mar 17]. Available from: https://dndi.org/research-development/portfolio/paediatric-benznidazole/
   Google Scholar
• World Health Organization (WHO). Leishmaniasis [Internet]. [cited 2021 Jan 27]. Available from: https://www.who.int/health-topics/leishmaniasis#tab=tab_1
   Google Scholar
• World Health Organization (WHO). Leishmaniasis [Internet]. [cited 2021 Jan 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
   Google Scholar
• Bezerra JMT, VEM DA, Barbosa DS, et al. Burden of leishmaniasis in brazil and federated units, 1990-2016: findings from global burden of disease study 2016. van Griensven J, editor. PLoS Negl Trop Dis. 2018;12(9):e0006697.
   PubMed Web of Science ®Google Scholar
• Olliaro P, Darley S, Laxminarayan R, et al. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Heal. 2009;14(8):918–925.
   PubMed Web of Science ®Google Scholar
• Reithinger R, Coleman PG. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting. BMC Infect Dis. 2007;7(1):3.
   PubMedGoogle Scholar
• World Health Organization (WHO). Leishmaniasis - Recommended treatment regimens for visceral leishmaniasis, ranked by preference [Internet]. [cited 2021 Apr 06]. Available from: www.who.int%2Fleishmaniasis%2Fresearch%2F978924129496_pp67_71.pdf&usg=AOvVaw3DM0cdH6d2fDbRBVmpdbhs
   Google Scholar
• World Health Organization. WHO. Schistosomiasis (Strategy) [Internet]. [cited 2021 Feb 1]. Available from: https://www.who.int/schistosomiasis/strategy/en/
   Google Scholar
• World Health Organization (WHO). Leishmaniasis - Access to essential antileishmanial medicines and treatment [Internet]. [cited 2021 Feb 1]. Available from: https://www.who.int/leishmaniasis/research/en/
   Google Scholar
• Rath S, Trivelin LA, Imbrunito TR, et al. Antimoniais empregados no tratamento da leishmaniose: estado da arte. Quim Nova. 2003;26(4):550–555.
   Google Scholar
• Frézard F, Demicheli C, Ribeiro R. Pentavalent antimonials: new perspectives for old drugs. Molecules. 2009;14(7):2317–2336.
   PubMed Web of Science ®Google Scholar
• Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58(2):265–278.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Broccatelli F. Oprea TI. BDDCS Applied to Over 900 Drugs. AAPS J. 2011;13(4):519–547.
   PubMed Web of Science ®Google Scholar
• Dinora G-E, Julio R, Nelly C, et al. In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm. 2005;295(1–2):93–99.
   PubMedGoogle Scholar
• El-Arini SK, Giron D, Leuenberger H. Solubility properties of racemic praziquantel and its enantiomers. Pharm Dev Technol. 1998;3(4):557–564.
   PubMedGoogle Scholar
• Maximiano FP, Costa GHY, Souza JD, et al. Caracterização físico-química do fármaco antichagásico benznidazol. Quim Nova. 2010;33(8):1714–1719.
   Google Scholar
• Ranjita S. Nanosuspensions: a new approach for organ and cellular targeting in infectious diseases. J Pharm Investig. 2013;43(1):1–26.
   Google Scholar
• Khandelwal A, Bahadduri PM, Chang C, et al. Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res. 2007;24(12):2249–2262.
   PubMed Web of Science ®Google Scholar
• Koto KS, Lescault P, Brard L, et al. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol. 2011;38(5):1329–1341.
   PubMed Web of Science ®Google Scholar
• Rodriques Coura J, De Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97(1):3–24.
   PubMed Web of Science ®Google Scholar
• Vicens Q, Westhof E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding a site. Structure. 2001;9(8):647–658.
   PubMed Web of Science ®Google Scholar
• Dorlo TPC, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67(11):2576–2597.
   PubMed Web of Science ®Google Scholar
• Barioni MB, Ramos AP, Zaniquelli MED, et al. Miltefosine and BODIPY-labeled alkylphosphocholine with leishmanicidal activity: aggregation properties and interaction with model membranes. Biophys Chem. 2015;196:92–99.
   PubMed Web of Science ®Google Scholar
• Kip AE, Schellens JHM, Beijnen JH, et al. Clinical pharmacokinetics of systemically administered antileishmanial drugs. Clin Pharmacokinet. 2018;57(2):151–176.
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–667.
   PubMed Web of Science ®Google Scholar
• Pax R, Bennett JL, Fetterer R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol. 1978;304(3):309–315.
   PubMed Web of Science ®Google Scholar
• Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2–3):141–159.
   PubMed Web of Science ®Google Scholar
• Gönnert R, Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Zeitschrift für Parasitenkd. 1977;52(2):129–150.
   PubMed Web of Science ®Google Scholar
• Harnett W. The anthelmintic action of praziquantel. Parasitol Today. 1988;4(5):144–146.
   PubMedGoogle Scholar
• Díaz de Toranzo EG, Castro JA, Franke de Cazzulo BM, et al. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids fromTrypanosoma cruzi. Experientia. 1988;44(10):880–881.
   PubMedGoogle Scholar
• Maya JD, Rodríguez A, Pino L, et al. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi. Biol Res. 2004;37(1):61–69.
   PubMed Web of Science ®Google Scholar
• Romanha AJ, Alves RO, Murta SMF, et al. Experimental chemotherapy against trypanosoma cruzi infection: essential role of endogenous interferon‐γ in mediating parasitologic cure. J Infect Dis. 2002;186(6):823–828.
   PubMed Web of Science ®Google Scholar
• Cirqueira MDL. Estudos estruturais da enzima nitrorredutase de Trypanosoma cruzi: caracterização do mecanismo de ativação dos pró-fármacos benznidazol e nifurtimox. [Ribeirão Preto]: Universidade de São Paulo; 2020.
   Google Scholar
• Stoppani AOM, Docampo R. Mode of action of nifurtimox and other nitro-derivatives on Trypanosoma cruzi. Med Argentina. 1980;40(1):10–16.
   Google Scholar
• Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother. 2012;56(1):115–123.
   PubMed Web of Science ®Google Scholar
• Mookerjee Basu J, Mookerjee A, Sen P, et al. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother. 2006;50(5):1788–1797.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–2581.
   PubMed Web of Science ®Google Scholar
• Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100:S17–20.
   PubMed Web of Science ®Google Scholar
• Coelho AC, Messier N, Ouellette M, et al. Role of the ABC Transporter PRP1 (ABCC7) in Pentamidine Resistance in Leishmania Amastigotes. Antimicrob Agents Chemother. 2007;51(8):3030–3032.
   PubMed Web of Science ®Google Scholar
• Tiuman TS, Santos AO, Ueda-Nakamura T, et al. Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011;15(8):e525–32.
   PubMed Web of Science ®Google Scholar
• Kumar Saha A, Mukherjee T, Bhaduri A. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol Biochem Parasitol. 1986;19(3):195–200.
   PubMed Web of Science ®Google Scholar
• Wijnant G-J, Van Bocxlaer K, Yardley V, et al. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. 2018;8(2):223–228.
   PubMed Web of Science ®Google Scholar
• Živanović V, Semini G, Laue M, et al. Chemical mapping of leishmania infection in live cells by SERS microscopy. Anal Chem. 2018;90(13):8154–8161.
   PubMed Web of Science ®Google Scholar
• Yamamoto ES, De Jesus JA, Bezerra-Souza A, et al. Tolnaftate inhibits ergosterol production and impacts cell viability of Leishmania sp. Bioorg Chem. 2020;102:104056.
   PubMed Web of Science ®Google Scholar
• ІL K, Romanina DM, Gladishev VV, et al. Study of the acute toxicity of the praziquantel using different routs of administration. Farm Zh. 2018;6:91–96.
   Google Scholar
• Miller DA, Hernandez S, Rodriguez De Armas L, et al. Tolerance of benznidazole in a united states chagas disease clinic. Clin Infect Dis. 2015;60(8):1237–1240.
   PubMed Web of Science ®Google Scholar
• Davies C, Dey N, Negrette OS, et al. Hepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: a comparison with Benznidazole. PLoS Negl Trop Dis. 2014;8(10):e3231.
   PubMed Web of Science ®Google Scholar
• Aldasoro E, Posada E, Requena-Méndez A, et al. What to expect and when: benznidazole toxicity in chronic Chagas’ disease treatment. J Antimicrob Chemother. 2018;73(4):1060–1067.
   PubMed Web of Science ®Google Scholar
• Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas’ disease). Biomed Environ Sci. 1988;1(1):19–33.
   PubMedGoogle Scholar
• Molina I, Salvador F, Sánchez-Montalvá A, et al. Toxic profile of benznidazole in patients with chronic chagas disease: risk factors and comparison of the product from two different manufacturers. Antimicrob Agents Chemother. 2015;59(10):6125–6131.
   PubMed Web of Science ®Google Scholar
• Crespillo-Andújar C, Chamorro-Tojeiro S, Norman F, et al. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. Clin Microbiol Infect. 2018;24(12):1344.e1–1344.e4.
   PubMed Web of Science ®Google Scholar
• Crespillo-Andújar C, López-Vélez R, Trigo E, et al. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Clin Microbiol Infect. 2020;26(3):384.e1–384.e4.
   PubMed Web of Science ®Google Scholar
• Pavan TBS, Silva JWD, Martins LC, et al. Hepatic changes by benznidazole in a specific treatment for Chagas disease. PLoS One. 2018;13(7):e0200707.
   PubMed Web of Science ®Google Scholar
• Buschini A, Ferrarini L, Franzoni S, et al. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. J Parasitol Res. 2009;136:463575.
   PubMedGoogle Scholar
• De Castro CR, EGD DT, Bernacchi AS, et al. Ultrastructural alterations in ovaries from nifurtimox or benznidazole-treated rats: their relation to ovarian nitroreductive biotransformation of both drugs. Exp Mol Pathol. 1989;50(3):385–397.
   PubMed Web of Science ®Google Scholar
• De Toranzo EG, Herrera DM, Castro JA. Rat liver nuclear nifurtimox nitroreductase activity. Res Commun Mol Pathol Pharmacol. 1997;98(3):249–254.
   PubMedGoogle Scholar
• González-Martin G, Thambo S, Paulos C, et al. The pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol. 1992;42(6):671–673.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Antimony Toxicity. Int J Environ Res Public Health. 2010;7(12):4267–4277.
   PubMed Web of Science ®Google Scholar
• Balaña-Fouce R, Reguera R, Cubrı́a J, et al. Pharmacology of Leishmaniasis. Gen Pharmacol Vasc Syst. 1998;30(4):435–443.
   PubMedGoogle Scholar
• Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011;118(2):87–96.
   PubMed Web of Science ®Google Scholar
• Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of america (idsa) and the american society of tropical medicine and hygiene (ASTMH). Clin Infect Dis. 2016;63(12):1539–1557.
   PubMedGoogle Scholar
• Fierer J, Hatlen L, Lin JP, et al. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob Agents Chemother. 1990;34(2):343–348.
   PubMed Web of Science ®Google Scholar
• Musa AM, Younis B, Fadlalla A, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis. 2010;4(10):e855.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–2581.
   PubMed Web of Science ®Google Scholar
• Clementi A, Battaglia G, Floris M, et al. Renal involvement in leishmaniasis: a review of the literature. Clin Kidney J. 2011;4(3):147–152.
   Google Scholar
• Diseases B (MD): NI of D and D and K. livertox: clinical and research information on drug-induced liver injury [internet]. 2012 [2021 Jan 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548946/
   Google Scholar
• Mladěnka P, Applová L, Patočka J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332–1403.
   PubMed Web of Science ®Google Scholar
• Vaamonde CA, Contreras GN, Diego JM. Sulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolones. In: Marc E. De Broe; George A. Porter; William M. Bennett; Gilbert Deray editors. Clinical Nephrotoxins. Dordrecht: Springer Netherlands; 2003. p. 223–470.
   Google Scholar
• Marcus Wharton J, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med. 1987;83(3):571–576.
   PubMed Web of Science ®Google Scholar
• Eisenhauer MD, Eliasson AH, Taylor AJ, et al. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389–395.
   PubMed Web of Science ®Google Scholar
• Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med. 1969;46(1):154–162.
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32(5):686–693.
   PubMed Web of Science ®Google Scholar
• Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–227.
   PubMed Web of Science ®Google Scholar
• Danaher PJ. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother. 2003;53(1):115–117.
   PubMed Web of Science ®Google Scholar
• Bandeira AC, Filho JM, de Almeida Ramos K. Reversible cardiomyopathy secondary to Amphotericin-B. Med Mycol Case Rep. 2016;13:19–21.
   PubMed Web of Science ®Google Scholar
• Vbr DS, Campos BRKL, de Oliveira JF, et al. Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine. Bioorg Med Chem. 2017;25(13):3259–3277.
   PubMed Web of Science ®Google Scholar
• Workman P, White RA, Walton MI, et al. Preclinical pharmacokinetics of benznidazole. Br J Cancer. 1984;50(3):291–303.
   PubMed Web of Science ®Google Scholar
• Raether W, Hänel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res. 2003;90(Supp 1):S19–39.
   PubMedGoogle Scholar
• Perin L, Moreira da Silva R, Fonseca KDS, et al. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice. Antimicrob Agents Chemother. 2017;61(4):4.
   Web of Science ®Google Scholar
• Pérez Montilla C, Moroni S, González N, et al. P38 Identification of Nifurtimox metabolites in urine of pediatric Chagas disease patients by UHPLC-MS/MS. Arch Dis Child. 2019;104(6):e32.3–e33.
   Google Scholar
• FDA Approved Products: lampit (nifurtimox) oral tablets [Internet]. [cited 2021 Feb 20]. Available from: https://www.accessdata.fda.gov
   Google Scholar
• Borborema SET, Osso Junior JA, Tempone AG, et al. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: a candidate formulation for visceral leishmaniasis. Biomed Pharmacother. 1609–16;2018:103.
   Google Scholar
• Kanyok TP, Killian AD, Rodvold KA, et al. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob Agents Chemother. 1997;41(5):982–986.
   PubMed Web of Science ®Google Scholar
• Bianciardi P, Brovida C, Valente M, et al. Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol. 2009;37(6):770–775.
   PubMed Web of Science ®Google Scholar
• Conte JE. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis. 1991;163(1):169–175.
   PubMed Web of Science ®Google Scholar
• Waalkes TP, Denham C, DeVita VT. Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther. 1970;11(4):505–512.
   PubMed Web of Science ®Google Scholar
• Vöhringer HF, Arasteh K, Link H, et al. [Determinants of serum pentamidine concentration in the human]. Med Klin. 1992;87(Suppl 1):24–29.
   Google Scholar
• Gershkovich P, Wasan EK, Sivak O, et al. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother. 2010;65(3):535–537.
   PubMed Web of Science ®Google Scholar
• Vale N, Gouveia MJ, Rinaldi G, et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61(5):5.
   Web of Science ®Google Scholar
• Castro JA, deMecca MM, Bartel LC. Toxic side effects of drugs used to treat chagas’ disease (american trypanosomiasis). Hum Exp Toxicol. 2006;25(8):471–479.
   PubMed Web of Science ®Google Scholar
• Cerisola JA, Neves da Silva N, Prata A, et al. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author’s transl)]. Bol Chil Parasitol. 1977;32(3–4):51–62.
   PubMedGoogle Scholar
• Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis. 2010;51(10):e69–75.
   PubMed Web of Science ®Google Scholar
• Maarouf M, Adeline MT, Solignac M, et al. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite. 1998;5(2):167–173.
   PubMed Web of Science ®Google Scholar
• Kotthaus J, Kotthaus J, Schade D, et al. New prodrugs of the antiprotozoal drug pentamidine. ChemMedChem. 2011;6(12):2233–2242.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Roy A, Sinha AK, et al. Improving outcome of treatment of kala-azar by supplementation of amphotericin b with physiologic saline and potassium chloride. Am J Trop Med Hyg. 2010;83(5):1040–1043.
   PubMed Web of Science ®Google Scholar
• MSF. Milhões aguardam inovações médicas para doenças negligenciadas [Internet]. 2012 [2019 Oct 22]. Available from: https://www.msf.org.br/noticias/milhoes-aguardam-inovacoes-medicas-para-doencas-negligenciadas
   Google Scholar
• DNDi. Desenvolvimento de novos medicamentos para doenças negligenciadas ainda enfrenta falhas fatais [Internet]. 2013 [2019 Dec 10]. Available from: http://www.dndi.org/2013/media-centre/langues-press-releases/fatal-imbalance-2-po/
   Google Scholar
• Ferreira LLG, Andricopulo AD. Drugs and vaccines in the 21st century for neglected diseases. Lancet Infect Dis. 2019;19(2):125–127.
   PubMed Web of Science ®Google Scholar
• Jain KK, editor. Drug Delivery Systems. (Methods in Molecular Biology<sup>TM{{/ sup}}; vol. 437). Totowa, NJ: Humana Press; 2008.
   Google Scholar
• Mehta VL, Chatterjee N. Drug delivery systems: past, present and future. J Int Med Sci Acad. 1995;8(3):78–86.
   Google Scholar
• Abu-Thabit NY, Makhlouf ASH. Historical development of drug delivery systems: from conventional macroscale to controlled, targeted, and responsive nanoscale systems. Makhlouf ASH, Abu-Thabit NY. editors. (Woodhead Publishing Series in Biomaterials). Stimuli responsive polymeric nanocarriers for drug delivery applications: volume 1: types and triggers [internet]. Sawston (UK): Woodhead Publishing; 3–41.2018.
   Google Scholar
• Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3–8.
   PubMed Web of Science ®Google Scholar
• Bruschi M. Strategies to modify the drug release from pharmaceutical systems. 1st Editio ed. Elsevier; 2015.
   Google Scholar
• Mukhekar S, Sumant O. Pharmaceutical drug delivery market by route of administration and application: global opportunity analysis and industry forecast, 2019-2026. Maharashtra (India): Allied Market Research; 2020.
   Google Scholar
• Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc. 2016;138(3):704–717.
   PubMed Web of Science ®Google Scholar
• Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):505–521.
   PubMed Web of Science ®Google Scholar
• Mehrizi TZ, Ardestani MS, Khamesipour A, et al. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major. J Mater Sci Mater Med. 2018;29(8):8.
   Web of Science ®Google Scholar
• Yang C, Xue B, Song W, et al. Reducing the toxicity of amphotericin B by encapsulation using methoxy poly(ethylene glycol)-: b -poly(l-glutamic acid- co -l-phenylalanine). Biomater Sci. 2018;6(8):2189–2196.
   PubMed Web of Science ®Google Scholar
• Hoffart V, Lamprecht A, Maincent P, et al. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release. 2006;113(1):38–42.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57(2):303–316.
   PubMed Web of Science ®Google Scholar
• Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2008;5(1):45–68.
   PubMed Web of Science ®Google Scholar
• Mansoor S, Kondiah PPD, Choonara YE, et al. Strategies for Insulin Delivery. Polymers (Basel). 2019;11(9):1380.
   PubMed Web of Science ®Google Scholar
• Sharma G, Sharma AR, Nam J-S, et al. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnology. 2015;13(1):74.
   PubMedGoogle Scholar
• Wong CY, Al-Salami H, Dass CR. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release. 2017;264:247–275.
   PubMed Web of Science ®Google Scholar
• Petkantchin V. The advantages of incremental pharmaceutical innovation. Bruxelles: Institut Économique Molinari Economic Note; 2012.
   Google Scholar
• Globerman S, Kristina M. Lybecker. In: Globerman S, Kristina M. Lybecker, editors.The Benefits of Incremental Innovation, focus on the pharmaceutical industry. Montreal, Toronto, Canada: Fraser institute.2014. 3–22.
   Google Scholar
• For B, Patients I, Business I. The value of incremental pharmaceutical innovation : innovation. 2009.
   Google Scholar
• GSK - GlaxoSmithKline Communications and Government Affairs. Incremental Innovation. GSK Public policy positions; 2014.
   Google Scholar
• Islan GA, Durán M, Cacicedo ML, et al. Nanopharmaceuticals as a solution to neglected diseases: is it possible? Acta Trop. 2017;170:16–42.
   PubMed Web of Science ®Google Scholar
• Research GV. Controlled release drug delivery market size, share & trends analysis report by technology (micro encapsulation, targeted delivery), by release mechanism, by application, by region, and segment forecasts, 2020–2027 [Internet]. 2020. Available from: https://www.grandviewresearch.com/press-release/global-controlled-release-drug-delivery-market
   Google Scholar
• Van Norman GA, Eisenkot R. Technology Transfer: from the Research Bench to Commercialization. JACC Basic to Transl Sci. 2017;2(1):85–97.
   PubMedGoogle Scholar
• Patents MP. Innovation: evidence from Economic History. J Econ Perspect. 2013 Feb;27(1):23–44.
   Web of Science ®Google Scholar
• How patents encourage innovation in technological development and deployment. [Internet]. [cited 2020 Jan 18]. Available from: https://www.irena.org/inspire/Intellectual-Property-Rights/Innovation
   Google Scholar
• Bhattacharya S, Saha C. Intellectual property rights: an overview and implications in pharmaceutical industry. J Adv Pharm Technol Res. 2011;2(2):88.
   PubMedGoogle Scholar
• Henderson R, Jaffe AB, Trajtenberg M. Universities as a source of commercial technology: a detailed analysis of university Patenting, 1965-1988. Rev Econ Stat. 1998;80(1):119–127.
   Web of Science ®Google Scholar
• D’Este P, Perkmann M. Why do academics engage with industry? The entrepreneurial university and individual motivations. J Technol Transf. 2011;36(3):316–339.
   Web of Science ®Google Scholar
• Chang S-H. The technology networks and development trends of university-industry collaborative patents. Technol Forecast Soc Change. 2017;118:107–113.
   Web of Science ®Google Scholar
• Meyer M. Academic patents as an indicator of useful research? A new approach to measure academic inventiveness. Res Eval. 2003;12(1):17–27.
   Web of Science ®Google Scholar
• Verbeek A, Debackere K, Luwel M, et al. Linking science to technology: using bibliographic references in patents to build linkage schemes. Scientometrics. 2002;54(3):399–420.
   Web of Science ®Google Scholar
• Cohen WM, Nelson RR, Walsh JP. Links and impacts: the influence of public research on industrial R&D. Manage Sci. 2002;48(1):1–23.
   Web of Science ®Google Scholar
• Rohrbeck R, Gemünden HG. Corporate foresight: its three roles in enhancing the innovation capacity of a firm. Technol Forecast Soc Change. 2011;78(2):231–243.
   Web of Science ®Google Scholar
• Ernst H. The use of patent data for technological forecasting: the diffusion of cnc-technology in the machine tool industry. Small Bus Econ. 1997;9(4):361–381.
   Web of Science ®Google Scholar
• Vrande VVD, Jong JPJD, Vanhaverbeke W. WIPO guide to using patent information [internet]. Vol. 29, Technovation. Geneva (Sswitzerland); 2009.  [cited 2021 Apr 06]. Available from: https://www.wipo.int/edocs/pubdocs/en/wipo_pub_l434_3.pdf
   Google Scholar
• Singh V, Chakraborty K, Vincent L. Patent database: their importance in prior art documentation and patent search. J Intellect Prop Rights. 2016;21(1):42–56.
   Google Scholar
• Archibugi D, Pianta M. Measuring technological change through patents and innovation surveys. Technovation. 1996;16(9):451–468.
   Web of Science ®Google Scholar
• Érdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the US patent citation network. Scientometrics. 2013;95(1):225–242.
   Web of Science ®Google Scholar
• Cho T-S, Shih H-Y. Patent citation network analysis of core and emerging technologies in Taiwan: 1997–2008. Scientometrics. 2011;89(3):795–811.
   Web of Science ®Google Scholar
• Song K, Kim KS, Lee S. Discovering new technology opportunities based on patents: text-mining and F-term analysis. Technovation 2017;60–61:1–14.
   Web of Science ®Google Scholar
• Jun S, Sung Park S, Sik Jang D. Technology forecasting using matrix map and patent clustering. Ind Manag Data Syst. 2012;112(5):786–807.
   Web of Science ®Google Scholar
• Ernst H. Patent information for strategic technology management. World Pat Inf. 2003;25(3):233–242.
   Google Scholar
• Yoon J, Seo W, Coh B-Y, et al. Identifying product opportunities using collaborative filtering-based patent analysis. Comput Ind Eng. 2017;107:376–387.
   Web of Science ®Google Scholar
• Basberg BL. Patents and the measurement of technological change: a survey of the literature. Res Policy. 1987;16(2–4):131–141.
   Web of Science ®Google Scholar
• Clark K, Cavicchi J, Jensen K, et al. Patent data mining: a tool for accelerating HIV vaccine innovation. Vaccine. 2011;29(24):4086–4093.
   PubMed Web of Science ®Google Scholar
• Kim YG, Suh JH, Park SC. Visualization of patent analysis for emerging technology. Expert Syst Appl. 2008;34(3):1804–1812.
   Web of Science ®Google Scholar
• Choi C, Park Y. Monitoring the organic structure of technology based on the patent development paths. Technol Forecast Soc Change. 2009;76(6):754–768.
   Web of Science ®Google Scholar
• Elvers D, Song CH, Steinbüchel A, et al. Technology trends in biodegradable polymers: evidence from patent analysis. Polym Rev. 2016;56(4):584–606.
   Web of Science ®Google Scholar
• Joung J, Kim K. Monitoring emerging technologies for technology planning using technical keyword based analysis from patent data. Technol Forecast Soc Change. 2017;114:281–292.
   Web of Science ®Google Scholar
• Gupta VK, Pangannaya NB. Carbon nanotubes: bibliometric analysis of patents. World Pat Inf. 2000;22(3):185–189.
   Google Scholar
• J-c D, Dutheuil C, Miquel J-F. Multidimensional analysis of trends in patent activity. Scientometrics. 2000;47(3):475–492.
   Web of Science ®Google Scholar
• Tseng Y-H, Lin C-J, Lin Y-I. Text mining techniques for patent analysis. Inf Process Manag. 2007;43(5):1216–1247.
   Web of Science ®Google Scholar
• Yoon B, Park Y. A text-mining-based patent network: analytical tool for high-technology trend. J High Technol Manag Res. 2004;15(1):37–50.
   Google Scholar
• Kim H, Song J. Social network analysis of patent infringement lawsuits. Technol Forecast Soc Change. 2013;80(5):944–955.
   Web of Science ®Google Scholar
• Kim G, Lee J, Jang D, et al. Technology clusters exploration for patent portfolio through patent abstract analysis. Sustain. 2016;8(12):1252.
   Web of Science ®Google Scholar
• Sarica S, Luo J, Wood KL. TechNet: technology semantic network based on patent data. Expert Syst Appl. 2020 Mar;142:112995.
   Web of Science ®Google Scholar
• Lee S, Yoon B, Park Y. An approach to discovering new technology opportunities: keyword-based patent map approach. Technovation. 2009;29(6–7):481–497.
   Web of Science ®Google Scholar
• Courtial JP, Callon M, Sigogneau A. The use of patent titles for identifying the topics of invention and forecasting trends. Scientometrics. 1993;26(2):231–242.
   Web of Science ®Google Scholar
• Daim TU, Rueda G, Martin H, et al. Forecasting emerging technologies: use of bibliometrics and patent analysis BT - tech mining: exploiting science and technology information resources. Technol Forecast Soc Change. 2006;73(8):981–1012.
   Web of Science ®Google Scholar
• Breitzman A, Thomas P. Using patent citation analysis to target/value M&A candidates. Res Manag. 2002;45(5):28–36.
   Google Scholar
• Mogee ME, Kolar RG. Patent co-citation analysis of Eli Lilly & Co. patents. Expert Opin Ther Pat. 1999;9(3):291–305.
   Web of Science ®Google Scholar
• Sjögren R, Stridh K, Skotare T, et al. Multivariate patent analysis—Using chemometrics to analyze collections of chemical and pharmaceutical patents. J Chemom. 2020:e3041.
   Web of Science ®Google Scholar
• Barth A. A deep analysis of chemical structure-based patent searching in the Derwent index space. World Pat Inf. 2018;53:49–57.
   Web of Science ®Google Scholar
• Downs GM, Barnard JM. Chemical patent information systems. Wiley Interdiscip Rev Comput Mol Sci. 2011;1(5):727–741.
   Web of Science ®Google Scholar
• Horne GA, Kinstrie R, Copland M. Novel drug therapies in myeloid leukemia: a patent review. Pharm Pat Anal. 2015;4(3):187–205.
   PubMed Web of Science ®Google Scholar
• Ö A, Peterson ML, The ZM. A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents. Pharm Pat Anal. 2012;1(3):313–327.
   PubMedGoogle Scholar
• Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: a patent review. Expert Opin Ther Pat. 2016;26(2):213–228.
   PubMed Web of Science ®Google Scholar
• Martins P, Rosa D, Fernandes AR, et al. Nanoparticle drug delivery systems: recent patents and applications in nanomedicine. Recent Patents Nanomed. 2013;3(2):105–118.
   Google Scholar
• Samad A, Ullah Z, Alam M, et al. Transdermal drug delivery system: patent reviews. Recent Pat Drug Deliv Formul. 2009;3(2):143–152.
   PubMedGoogle Scholar
• Akinsolu FT, de Paiva VN, Souza SS, et al. Patent landscape of neglected tropical diseases: an analysis of worldwide patent families. Global Health. 2017;13(1):82.
   PubMedGoogle Scholar
• Patent Analysis MH. Anti-infectives: antituberculosis drugs: patent analysis 1990–1995. Expert Opin Ther Pat. Washington, D.C., USA: White Paper, NASA; 1996;6(2):187–190.
   Web of Science ®Google Scholar
• Mankins. JC. Technology Readiness Levels. 1995.
   Google Scholar
• Tomaschek K, Olechowski A, Eppinger S, et al. Survey of technology readiness level users. INCOSE Int Symp. 2016;26(1):2101–2117.
   Google Scholar
• Bakke K, Haskins C. Use of TRL in the systems engineering toolbox. INCOSE Int Symp. 2018;28(1):587–601.
   Google Scholar
• Velho SRK, Simonetti ML, Souza CRPD, et al. Nível de Maturidade Tecnológica: uma sistemática para ordenar tecnologias. Parc Estrat. 2017;22(n. 45):119–140.
   Google Scholar
• Mankins JC. Technology readiness assessments: a retrospective. Acta Astronaut. 2009;65(9–10):1216–1223.
   Web of Science ®Google Scholar
• Olechowski A, Eppinger SD, Joglekar N. Technology readiness levels at 40: a study of state-of-the-art use, challenges, and opportunities. In: PICMET/IEEE, editor. 2015 portland international conference on management of engineering and technology (PICMET). IEEE; 2015. 2084–2094.
   Google Scholar
• EARTO (European Association of Research and Technology Organizations). The TRL Scale as a Research & Innovation Policy Tool. EARTO Recommendations,  Brussels (Belgium); 2014.
   Google Scholar
• European Commission. Drawing funding and financing scenarios for effective implementation of Smart Specialisation Strategies. JRC Technical reports. Seville (Spain); 2018.
   Google Scholar
• EMBRAPA. Sistema EMBRAPA de Gestão, Manual sobre o Uso da Escala TRL/MRL. 2018.
   Google Scholar
• ISO. ISO 16290:2013 Space systems- Definition of the Technology Readiness Levels and their criteria of assessment. Iso 16290:2013. Geneva (Switzerland); 2013.
   Google Scholar
• European Union Horizons 2020 Framework Programme for Research and Innovation - European Commission Decision C (2014)4995 of 22 July 2014, “Horizon 2020 work programme 2014–2015” [Internet]. 2014. [cited 2021 Apr 06]. Available from: https://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-intro_en.pdf
   Google Scholar
• Zimmermann AW, Schomäcker R. Assessing early-stage CO2 utilization technologies—comparing apples and oranges? Energy Technol. 2017 Jun 1;5(6):850–860.
   Web of Science ®Google Scholar
• Medical Countermeasure Products. DOD Medical TRLs and May 2008 HHS PHEMCE TRLs [Internet]. [cited 2019 Nov 5]. Available from: https://www.medicalcountermeasures.gov/trl/integrated-trls/
   Google Scholar
• Jovic Cantab TM MRCS, Jessop Cantab ZM MRCS, Firmin F, et al. Professor Iain Whitaker MA Cantab FRCS Plast DS. 3D bioprinting for surgical reconstruction & organ transplantation. London (UK): Future Medicine Ltd London; 2018.
   Google Scholar
• Eaton MAW, Levy L, Fontaine OMA. Delivering nanomedicines to patients: a practical guide. Nanomedicine Nanotechnology, Biol Med. 2015;11(4):983–992.
   PubMed Web of Science ®Google Scholar
• NATO. Development of an assessment methodology for demonstrating usability, technical maturity, and operational benefits of advanced medical technology. Vol. TR-HFM-130. Brussels (Belgium): RTO/NATO; 2010.
   Google Scholar
• Engel D, Dalton A, Dale C, et al. Development of a risk-based comparison methodology of carbon capture technologies. Greenh Gases Sci Technol. 2014;4(3):316–330.
   Web of Science ®Google Scholar
• Gabriela M. From lab to large-scale development of clinically compliant nanopharmaceutics from lab to large-scale development of clinically compliant nanopharmaceutics. Coimbra (Portugal): Universidade de Coimbra; 2017.
   Google Scholar
• Ofício EMBRAPII n°098/2019. Manual de orientação operacional n° 02/2019 [Internet]. [cited 2021 Apr 06]. Available from: https://embrapii.org.br/wp-content/images/2019/05/0705_Orientacao_Operacional_02-19.pdf
   Google Scholar
• Debois S, Hildebrandt T, Marquard M, et al. Bridging the valley of death: a success story on danish funding schemes paving a path from technology readiness level 1 to 9. In: 2015 IEEE/ACM 2nd International Workshop on Software Engineering Research and Industrial Practice. NW Washington, DC United States: IEEE; 2015. 54–57.
   Google Scholar
• Malone P, Smoker R, Apgar H, et al. The application of TRL metrics to existing cost prediction models. In: 2011 Aerospace Conference. Big Sky, MT, USA : IEEE; 2011. p. 1–12.
   Google Scholar
• Tierney R, Hermina W, Walsh S. The pharmaceutical technology landscape: a new form of technology roadmapping. Technol Forecast Soc Change. 2013;80(2):194–211.
   Web of Science ®Google Scholar
• Vella PC, Dimov SS, Minev R, et al. Technology maturity assessment of micro and nano manufacturing processes and process chains. Proc Inst Mech Eng Part B J Eng Manuf. 2018;232(8):1362–1383.
   Web of Science ®Google Scholar
• Contreras L, Lely A, Ávila L, et al., (Colombia): “‘Análisis de Datos en Cuerpo Estático Basado en IMUS.’” Memorias de la Séptima Conferencia Iberoamericana de Complejidad, Informática y Cibernética: CICIC 2017. In: Modelos para Analisar Níveis de Prontidão de Inovação [Internet]. 2017. p. 82–86. Available from: http://www.iiis.org/CDs2017/CD2017Spring/bookC1.htm
   Google Scholar
• Sauser B, Gove R, Forbes E, et al. Integration maturity metrics: development of an integration readiness level. Inf Knowl Syst Manag. 2010;9(1):17–46.
   Google Scholar
• Weber J, Costello R, Ringwood J. WEC technology performance levels (TPLs) - metric for successful development of economic WEC Technology. Aalborg, Denmark: EWTEC2013; 2013.
   Google Scholar
• Lemos JC, Chagas MF. Application of maturity assessment tools in the innovation process: converting system’s emergent properties into technological knowledge. RAI Rev Adm E Inovação. 2016;13(2):145–153.
   Google Scholar
• Stromgren C, Lara G, Hendrickson J, et al. Investment Portfolio Prioritization for Emerging Homeland Security Threats. In: 18 Winter Simulation Conference, editor. Proceedings of the 2018 Winter Simulation Conference [Internet]. Gothenburg Sweden : IEEE Press; 2018. 2769–2780. (WSC ’18). Available from: http://dl.acm.org/citation.cfm?id=3320516.3320846
   Google Scholar
• Tan RR, Aviso KB, Ng DKS. Optimization models for financing innovations in green energy technologies. Renewable Sustainable Energy Rev. 2019;113:109258.
   Web of Science ®Google Scholar
• Ye J, D`Angelo L, Viteri M, et al. Comparison of Technology Qualification Approaches. In: Offshore Technology Conference. Houston, Texas, USA: Offshore Technology Conference; 2017.
   Google Scholar
• Engel DW, Dalton AC, Anderson KK, et al. Development of Technology Readiness Level (TRL) Metrics and Risk Measures [Internet]. Richland, WA (United States); 2012 Oct. [cited 2021 Apr 06]. Available from:http://www.osti.gov/servlets/purl/1067968/
   Google Scholar
• Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov. 2015;14(4):279–294.
   PubMed Web of Science ®Google Scholar
• DNDi. Pharmaceutical Development Manager. Geneva, Switzerland: DNDi; 2019.
   Google Scholar
• Pécoul B. New drugs for neglected diseases: from pipeline to patients. PLoS Med. 2004;1(1):e6.
   PubMed Web of Science ®Google Scholar
• Cerize NNP, De Oliveira AM, Ré MI, et al. Colloidal nanoscale carriers for active hydrophilic substances and method for producing same. BR: WO2011156880A1; 2013.
   Google Scholar
• Processo para obtenção de dispersões sólidas utilizando alginato de sódio como biopolímero e produto obtido. BR: BR102016030992; 2016.
   Google Scholar
• Injection used for treating blood-sucking insect diseases. preferably schistosomiasis infection, contains poloxamer, soybean lecithin, sodium stearate, phosphatidyl ethanolamine, polyethylene glycol, praziquantel and glyceryl behenate. CN: CN103381141-A; 2012.
   Google Scholar
• Leonardo Fernandes Fraceto, Luciana de Matos Alves Pinto, Eneida de Paula, Antonio Carlos Senges Lino, Marcelo Bispo de Jesus, Yuji Takahata, inventor. Composto de inclusão entre b-ciclodextrina e praziquantel para tratamento de esquistossomose. BR: PI0401621–1; 2004.
   Google Scholar
• VANESSA CARLA FURTADO MOSQUEIRA, LILIAN TEIXEIRA OLIVEIRA, RAQUEL GOMES CASTANHEIRA, inventor. Pharmaceutical composition used in human and veterinary medicine for treating Chagas disease. In: leishmaniasis, African sleeping sickness and tumors, comprises benznidazole drug associated with nanoestructures. BR: BR102013023902; 2013. 21.
   Google Scholar
• PEDRO JOSÉ ROLIM NETO, LESLIE RAPHAEL DE MOURA FERRAZ, SALVANA PRISCYLLA MANSO COSTA, LARISSA ARAÚJO ROLIM, CYBELLY MARQUES DE MELO, ROSALI MARIA FERREIRA DA SILVA, SEVERINO ALVES JÚNIOR, ALINNE ÉLIDA GONÇALVES ALVES, DÉBORA DOLORES SOUZA DA SILVA NASCINEMTO, ISABELA ARAÚJO E AMARIZ, inventor. Formulações farmacêuticas contendo associação de benznidazol e MOF’s para obtenção tecnológica de sistemas drug delivery. BR: BR1020160034086; 2016. 7.
   Google Scholar
• Arnóbio Antônio da Silva Junior, Letícia Streck, Anselmo Gomes de Oliveira, inventor. Composições e processo de produção da forma líquida de administração a base de sistemas lipídicos emulsionados. In: do tipo emulsão, microemulsão e/ou nanoemulsão contendo benznidazol para o tratamento da doença de Chagas. BR: BR1020120194287; 2012. 9.
   Google Scholar
• Processo para obtenção de complexos de inclusão de benznidazol com derivados de ciclodextrinas. BR: PI0903451–0; 2009. 16.
   Google Scholar
• Jose Lamartine Soares Sobrinho, Pedro José Rolim Neto, Marcílio Sergio Soares da Cunha, Juan Torres Labandeira, inventor. Composição e método de produção de sistemas nanoparticulados para liberação modificada de benznidazol. BR1020170244482; 2017.
   Google Scholar
• Composições farmacêuticas de posaconazol e benznidazol com incremento da dissolução. BR1020160238005; 2016.
   Google Scholar
• PEDRO JOSÉ ROLIM NETO, CAMILA BEZERRA MELO FIGUEIRÊDO, PING I. LEE, ANA CARLA QUINTAS DE MEDEIROS VIEIRA, GIOVANNA CHRISTINNE ROCHA DE MEDEIROS SCHVER, JOSÉ LAMARTINE SOARES SOBRINHO, Monica Felts de La Roca Soares, inventor. Formulation useful for controlled release of nifurtimox and treating chagas disease comprises nifurtimox, water-swellable hydrophilic polymer and binder e.g. microcrystalline cellulose. US: WO2013169925-A1; 2012.
   Google Scholar
• BEJARANO ROSEMARY OCHOA, DEMELO ALAN LANE, DEMICHELE CYNTHIA PERES, FERREIRA LUCAS ANTONIO MIRANDA, FREZARD FREDERIC JEAN GEORGES, MILLAN RUBEN DARIO SINISTERRA, inventor. Preparation of compounds used for preparing composition for treating e.g. leishmaniasis, comprises mixing antimony derivatives with cyclodextrins in aqueous solution or in solid state. BR: WO2006000069; 2006.
   Google Scholar
• Cynthia Peres Demichele, Frederic Jean Georges Frezard, Alan Lane de Melo, Lucas Antonio Miranda Ferreira, Ruben Dario Sinisterra Millan; Rosemary Ochoa Bejarano, inventors. Processo de preparação de compostos entre as ciclodextrinas ou seus derivados e o antimÈnio ou seus derivados, de formulações farmaceuticas contendo esses compostos e produtos associados, para o tratamento das leishmanioses e da esquistossomose. BR: C10304952–3 (PI0304952-3); 2004. 29.
   Google Scholar
• Domenico BRITTI, Donato Cosco, Massimo Fresta, Donatella Paolino, Elena TRAPASSO, inventors. Nanoparticles used for preventing and treating pathologies due to infection with Leishmania in animal and humans comprise polylactic acid shell and aqueous core including antimonial compound. WO2015177820; 2014.
   Google Scholar
• ALVING CARL R, STECK EDGAR A, inventors. Liposome encapsulated anti-leishmaniasis antimonial drug|formed by wetting lipid film with drug soln., mixing and removing excess drug soln. US: US4186183; 1980.
   Google Scholar
• APARECIDA REZENDE SIMONE, GUILHERME AZEVEDO ERLY, JEAN GEORGES FREZARD FREDERIC, MAGNO DA SILVA SYDNEI, PERES DEMICHELI CYNTHIA, RIO RIBEIRO RAUL, inventors. Pharmaceutical composition used for producing medicament for treatment of visceral leishmaniasis in mammals, comprises combination of conventional liposomes and prolonged circulating liposomes incorporating antileishmanial drugs. BR: WO2013131164; 2012.
   Google Scholar
• NATÁLIA NETO PEREIRA CERIZE; THAIS ARAGÃO HOROIWA, Adriano Marim de Oliveira, inventors. Nanocarreadores coloidais para veiculação tópica do antimoniato de meglumina. BR: BR1020160034434; 2016.
   Google Scholar
• RAO LEBURU S, inventor. Stable liposome(s) of antimony contg. drug|for treatment of Leishmania infection. GB: US4594241-A; 1983.
   Google Scholar
• ALI NAHID, BHOWMICK SWATI P, GHOSE JAYEETA, inventor. Liposomal formulation useful as leishmanicidal agent, comprises single dose of antileishmanial antimonial drug encapsulated in cationic liposome consisting of neutral lipid and cationic lipid in specific molar ratio. IN: US2012207821; 2005.
   Google Scholar
• MARIA NORMA MELO; JOSÉ DIAS CORREA JÚNIOR; FRÉDÉRIC JEAN GEORGES FRÉZARD; BETÂNIA MARA ALVARENGA; KELLY CRISTINA KATO, inventors. Reports JC, Indicators ES. Liposomal formulation useful as leishmanicidal agent for treatment of kala azar, comprises amount of antileishmanial antimonial drugs encapsulated in sub optimal dose of cationic liposome, where ratio of lipid to drug is specified. IN: US2007026061; 2005.
   Google Scholar
• Processo de preparação de nanocompósitos fosfatados biocompatíveis, produtos e usos. BR: BR102013032731; 2013.
   Google Scholar
• ALVES BANDEIRA FALCAO CAMILA, PACIENZA LIMA WALLACE, ROSSI BERGMANN BARTIRA, inventors. Pharmaceutical composition for preparing medicine for treating parasitosis and infectious skin diseases in dermis regions e.g. leishmaniasis, comprises antiparasitic medicine that is encapsulated in poly(lactic-co-glycolic acid) particles. BR: WO</Collab>2013010238; 2011.
   Google Scholar
• BILBAO RAMOS PABLO ESTANISLAO; BOLAS FERNANDEZ FRANCISCO, DEA AYUELA MARIA AUXILIADORA, MOLERO MARTIN-PORTUGUES GLORIA, NOMBELA CANO CESAR; RUIZ SALDANA HELGA KARINA, SERRANO LOPEZ REMEDIOS, TORRADO DURAN JUAN JOSE, VEGAS SANCHEZ MARIA DEL CARMEN, inventors.Topical pharmaceutical formulation used for treating fungal infection (cutaneous and mucocutaneous mycoses) and parasitic infections (cutaneous leishmaniasis) in humans, comprises complex of monomeric amphotericin B and gamma-cyclodextrin. ES: WO2012042072; 2010.
   Google Scholar
• Maria Mainardes, Najeh Maissar Kahalil, Diani Mesa Casa, Luciana Facco Dalmolin, Talita Cristina Moreira Moraes Carraro, Calorine Antunes Danziato, inventors.Processo de obtenção de nanopartículas poliméricas contendo o fármaco anfotericina B. BR: PI1107205–9; 2011.
   Google Scholar
• OSÉ MARIO BARICHELLO, RENATA ALVES DE OLIVEIRA E CASTRO, LUCAS ANDRADE FERREIRA, ELIETE MARIA COSTA, ANA PAULA DE BATTISTI RIBEIRO, SIMONE APARECIDA REZENDE, inventors. Sistema micelar termo reversível contendo anfotericina b para administração subcutânea e tópica no tratamento da leishmaniose visceral e tegumentar. BR1020140307729; 2014.
   Google Scholar
• ANDRÉ AUGUSTO GOMES FARACO, JUÇARA RIBEIRO FRANCA, TATIANA GOMES RIBEIRO, RACHEL OLIVEIRA CASTILHO, EDUARDO ANTONIO FERRAZ COELHO, MIGUEL ANGEL CHÁVEZ FUMAGALLI , inventors. Uso de nanopartículas de quitosana e condroitina para o tratamento de leishmaniose. BR1020130178810; 2013.
   Google Scholar
• Shoukath M Ali, Moghis U Ahmad, Ateeq Ahmad; Saifuddin Sheikh, Imran Ahmad, inventors. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof. WO2008127358; 2006.
   Google Scholar
• Jitendra Nath Verma, Lily Verma, Krishan Kumar Tripathi, inventors. Composition, useful for the treatment of infections, comprises sterol enriched mixed lamellarity amphotericin intercalating liposomes in aqueous suspension. WO2005120460; 2004.
   Google Scholar
• HU JING, WEI PENG, YIN JIAN, inventors. Targeted pharmaceutical composition loaded with amphotericin B and adriamycin together and application thereof. CN: CN110801433; 2019.
   Google Scholar
• VANESSA CRISTINA RESCIA, CLAUDETE JUSTINA VALDUGA, SUSANA NOGUEIRA DINIZ, inventors. Formulação de nanoemulsões contendo miltefosina em associação com betaglucana extraída de saccharomyces cerevisiae por micro-ondas e seu uso. BR: BR102019007133; 2019.
   Google Scholar
• SYDNEI MAGNO DA SILVA, KAREN FERRAZ FARIA, FREDERIC JEAN GEORGES FREZARD, JULIANE SOUSA LANZA, RENATA CRISTINA DE PAULA, inventors. Formulação lipossomal para o tratamento das leishmanioses. BR: BR1020170025829; 2017. 5.
   Google Scholar
• Wouters OJ, McKee M, Luyten J. estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844.
   PubMed Web of Science ®Google Scholar
• Stegemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31(5):249–261.
   PubMed Web of Science ®Google Scholar
• Leonardi D, Bombardiere ME, Salomon CJ. Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats. Int J Biol Macromol. 2013;62:543–548.
   PubMed Web of Science ®Google Scholar
• de Moura Ferraz LR, Aéga T, Dds DSN, et al. ZIF-8 as a promising drug delivery system for benznidazole: development, characterization, in vitro dialysis release and cytotoxicity. Sci Rep. 2020;10(1):16815.
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Oliveira LT, Gonçalves KR, et al. Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment. Eur J Pharm Sci. 2020;145:105234.
   PubMed Web of Science ®Google Scholar
• Molina I. Final report summary - BERENICE (benznidazol and triazol research group for nanomedicine and innovation on chagas disease) [Internet]. EUROPEAN COMMISSION. [cited 2021 Mar 4]. Available from: https://cordis.europa.eu/project/id/305937/reporting
   Google Scholar
• Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1–2):137–144.
   PubMedGoogle Scholar
• Maragos S, Archontaki H, Macheras P, et al. Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. AAPS PharmSciTech. 2009;10(4):1444–1451.
   PubMed Web of Science ®Google Scholar
• Dametto PR, Dametto AC, Polese L, et al. Development and physicochemical characterization of solid dispersions containing praziquantel for the treatment of schistosomiasis. J Therm Anal Calorim. 2017;127(2):1693–1706.
   Web of Science ®Google Scholar
• Amara RO, Ramadan AA, El-Moslemany RM, et al. Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int J Nanomedicine. 2018;13:4493–4505.
   PubMed Web of Science ®Google Scholar
• Borrego-Sánchez A, Sánchez-Espejo R, García-Villén F, et al. Praziquantel–clays as accelerated release systems to enhance the low solubility of the drug. Pharmaceutics. 2020;12(10):914.
   Web of Science ®Google Scholar
• Andrade LN, Marques C, Barbosa T, et al. Praziquantel-loaded solid lipid nanoparticles: production, physicochemical characterization, release profile, cytotoxicity and in vitro activity against Schistosoma mansoni. J Drug Deliv Sci Technol. 2020;58:101784.
   Web of Science ®Google Scholar
• Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv. 2014;21(6):406–411.
   PubMed Web of Science ®Google Scholar
• Zheng X-S, Duan C-Z, Xiao Z-D, et al. Transdermal delivery of praziquantel: effects of solvents on permeation across rabbit skin. Biol Pharm Bull. 2008;31(5):1045–1048.
   PubMed Web of Science ®Google Scholar
• Wang L, Zheng X, Fang Y, et al. Transdermal evaporation delivery system of praziquantelfor schistosomiasis japonicum chemotherapy. J Pharm Sci. 2011;100(7):2769–2777.
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487–1490.
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–149.
   PubMed Web of Science ®Google Scholar
• Poovi G, Damodharan N. Lipid nanoparticles: a challenging approach for oral delivery of BCS Class-II drugs. Futur J Pharm Sci. 2018;4(2):191–205.
   Web of Science ®Google Scholar
• Silva P, Bonifácio B, Ramos M, et al. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine. 2013;9:1–15.
   PubMed Web of Science ®Google Scholar
• A. A, A. M, F. P. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. In: Recent Advances in Novel Drug Carrier Systems [Internet]. InTech; 2012. [cited 2021 Apr 6].  Available from: http://www.intechopen.com/books/recent-advances-in-novel-drug-carrier-systems/lipid-nanoparticulate-drug-delivery-systems-a-revolution-in-dosage-form-design-and-development
   Google Scholar
• Severino P, Andreani T, Macedo AS, et al. Current state-of-art and new trends on lipid nanoparticles (sln and nlc) for oral drug delivery. J Drug Deliv. 2012;2012:1–10.
   Google Scholar
• Esfandiari F, Motazedian MH, Asgari G, et al. Paromomycin-loaded mannosylated chitosan nanoparticles: synthesis, characterization and targeted drug delivery against leishmaniasis. Acta Trop. 2019;197.
   Google Scholar
• Kumar R, Pandey K, Sahoo GC, et al. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis. Mater Sci Eng C. 2017;75:1465–1471.
   PubMed Web of Science ®Google Scholar
• Sánchez G, Cuellar D, Zulantay I, et al. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol Res. 2002;35(1):1.
   Web of Science ®Google Scholar
• Durand R, Paul M, Rivollet D, et al. Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite. 1997;4(4):331–336.
   PubMed Web of Science ®Google Scholar
• Hua S, MBC DM, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
   PubMed Web of Science ®Google Scholar
• JOSÉ DIAS CORREA JÚNIOR, FRÉDÉRIC JEAN GEORGES FRÉZARD, BETÂNIA MARA ALVARENGA, MARIA NORMA MELO, KELLY CRISTINA KATO, inventors. Nanocompósitos fosfatados biocompatíveis contendo antimônio, processo de preparação e usos. BR: BR132015031111; 2015.
   Google Scholar
• Matot I, Pizov R. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med. 2000;28(7):2528–2532.
   PubMed Web of Science ®Google Scholar
• Vogelsinger H. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153–1160.
   PubMed Web of Science ®Google Scholar
• Mistro S, Gomes B, Rosa L, et al. Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis. Trop Med Int Heal. 2017;22(12):1569–1578.
   PubMed Web of Science ®Google Scholar
• Meyerhoff AUS. Food and drug administration approval of ambisome (liposomal amphotericin b) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28(1):42–48.
   PubMed Web of Science ®Google Scholar
• Teixeira MC, Carbone C, Souto EB. Beyond liposomes: recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery. Prog Lipid Res. 2017;68:1–11.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15–28.
   PubMed Web of Science ®Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4(3):95–99.
   PubMed Web of Science ®Google Scholar
• Karim K, Mandal A, Biswas N, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010;1(4):374–380.
   PubMedGoogle Scholar
• Ge X, Wei M, He S, et al. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2):55.
   PubMed Web of Science ®Google Scholar
• Yeo PL, Lim CL, Chye SM, et al. Niosomes: a review of their structure, properties, methods of preparation, and medical applications. Asian Biomed. 2017;11(4):301–313.
   Web of Science ®Google Scholar
• Chen S, Hanning S, Falconer J, et al. Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019;144:18–39.
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother. 1997;41(4):752–756.
   PubMed Web of Science ®Google Scholar
• Mostafavi M, Sharifi I, Farajzadeh S, et al. Niosomal formulation of amphotericin B alone and in combination with glucantime: in vitro and in vivo leishmanicidal effects. Biomed Pharmacother. 2019;116:108942.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Jarho P, Másson M, et al., **(Loftsson T. is a leading cyclodextrin researcher with decades of research and contributions in this field). Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2(2):335–351.
   PubMedGoogle Scholar
• Loftsson T, Hreinsdóttir D, Másson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005;302(1–2):18–28.
   PubMed Web of Science ®Google Scholar
• Li H, Xu X, Liu M, et al. Microcalorimetric and spectrographic studies on host-guest interactions of α-, β-, γ- And Mβ-cyclodextrin with resveratrol. Thermochim Acta. 2010;510(1–2):168–172.
   Web of Science ®Google Scholar
• Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharm. 2018;535(1–2):272–284.
   PubMed Web of Science ®Google Scholar
• Duchêne D, Bochot A. Thirty years with cyclodextrins. Int J Pharm. 2016;514(1):58–72.
   PubMedGoogle Scholar
• Saokham P, Muankaew C, Jansook P, et al. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018;23(5):1161.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–1025.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Salústio PJ, Pontes P, Conduto C, et al. Advanced technologies for oral controlled release: cyclodextrins for oral controlled release. AAPS PharmSciTech. 2011;12(4):1276–1292.
   PubMed Web of Science ®Google Scholar
• Hirlekar RS, Sonawane SN, Kadam VJ. Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility. AAPS PharmSciTech. 2009;10(3):858–863.
   PubMed Web of Science ®Google Scholar
• Li J, Xiao H, Li J, et al. Drug carrier systems based on water-soluble cationic β-cyclodextrin polymers. Int J Pharm. 2004;278(2):329–342.
   PubMedGoogle Scholar
• Loftsson T, Másson M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Deliv Sci Technol. 2004;14(1):35–43.
   Web of Science ®Google Scholar
• Lyra MAM, Soares-Sobrinho JL, Figueiredo RCBQ, et al. Study of benznidazole-cyclodextrin inclusion complexes, cytotoxicity and trypanocidal activity. J Incl Phenom Macrocyclic Chem. 2012;73(1–4):397–404.
   Web of Science ®Google Scholar
• Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: markov models. Am J Trop Med Hyg. 2005;73(5):901–910.
   PubMed Web of Science ®Google Scholar
• CNPq. Edital MCT/CNPq/CTSaúde n° 11/2006 Estudo da Dengue. Brasilia(Brasil); 2006.
   Google Scholar
• CNPq. Edital MCT/CNPq/MS-SCTIE-DECIT n° 25/2006 Estudo de Doenças Negligenciadas. Brasilia(Brasil); 2006.
   Google Scholar
• CNPq. Edital MCT/CNPq/CT-Saúde/MS/SCTIE/DECIT n° 34/2008 Doenças Negligenciadas. Brasilia(Brasil); 2008.
   Google Scholar
• CNPq. Edital MCT/CNPq N° 073 2009 PRONEX Rede Dengue. Brasilia(Brasil); 2009.
   Google Scholar
• CNPq. Edital n° 41/2012 Convênio CNPq/GSK (GlaxoSmithKline). Brasilia(Brasil); 2012.
   Google Scholar
• CNPq. Edital MCTI-CNPq-MS-SCTIE-Decit n° 40–2012 Pesquisa em Doenças Negligenciadas. Brasilia(Brasil); 2012.
   Google Scholar
• CNPq. Edital CNPq/MS/SCTIE/DECIT n° 37/2014 Pesquisas sobre Helmintíases. Brasilia(Brasil); 2014.
   Google Scholar
• CNPq. Edital CNPq-MS-SCTIE-DECIT n° 31/2014 Pesquisas sobre Doença de Chagas. Brasilia(Brasil); 2014.
   Google Scholar
• CNP. Edital CNPq/MS/SCTIE/DECIT/SVS/DST n° 30/2014. Brasilia(Brasil); 2014.
   Google Scholar
• CNPq. Edital CNPq/MS/SCTIE/DECIT n° 32/2014 Pesquisas sobre Leishmanioses. Brasilia(Brasil); 2014.
   Google Scholar
• BRASIL. Lei [Internet]. BRASIL; 2004. Available from: http://www.planalto.gov.br/ccivil_03/_ato2004-2006/2004/lei/l10.973.htm
   Google Scholar
• BRASIL - MINISTÉRIO DA CIÊNCIA, TECNOLOGIA IEC. Política de propriedade intelectual das instituições científicas, tecnológicas e de inovação do brasil relatório formict 2016 política de propriedade intelectual das instituições científicas e tecnológicas e de inovação do brasil [internet]. 2017. [cited 2021 Apr 6]. Available from: https://www.mctic.gov.br/mctic/export/sites/institucional/tecnologia/propriedade_intelectual/arquivos/Relatorio-Formict-Ano-Base-2016.pdf
   Google Scholar
• Wang G, Guan J. The role of patenting activity for scientific research: a study of academic inventors from China’s nanotechnology. J Informetr. 2010;4(3):338–350.
   Web of Science ®Google Scholar
• Mowery DC, Nelson RR, Sampat BN, et al. The growth of patenting and licensing by U.S. universities: an assessment of the effects of the Bayh–Dole act of 1980. Res Policy. 2001;30(1):99–119.
   Web of Science ®Google Scholar
• Wong C-Y, Goh K-L. Growth behavior of publications and patents: a comparative study on selected Asian economies. J Informetr. 2010;4(4):460–474.
   Web of Science ®Google Scholar
• Sampat BN. Patenting and US academic research in the 20th century: the world before and after Bayh-Dole. Res Policy. 2006;35(6):772–789.
   Web of Science ®Google Scholar
• Geuna A, Nesta LJJ. University patenting and its effects on academic research: the emerging European evidence. Res Policy. 2006;35(6):790–807.
   Web of Science ®Google Scholar
• Póvoa LMC. Patentes de universidades e institutos públicos de pesquisa e a transferência de tecnologia para empresas no Brasil. Universidade Federal de Minas Gerais; 2008.
   Google Scholar
• Silva K. Patentes acadêmicas no Brasil: um novo panorama de contribuição das universidades na via PCT. Lisboa, Portugal: Lisboa School of Economics & Management; 2014.
   Google Scholar
• World Health Organization (WHO). WHO, Lymphatic filariasis, Partnership [Internet]. [cited 2020 Sep 2]. Available from: https://www.who.int/lymphatic_filariasis/partnership/en/
   Google Scholar
• Ridley RG. Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experience with public-private partnerships. EMBO Rep. 2003 Jun 9;4( SPEC. ISS.). DOI:https://doi.org/10.1038/sj.embor.embor858.
   Google Scholar
• Bush S, Hopkins AD. Public-private partnerships in neglected tropical disease control: the role of nongovernmental organisations. Acta Trop. 2011;120(Suppl. 1):S169–72.
   PubMedGoogle Scholar
• Erratum MM. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need (PLoS Medicine (2005) 2:9. PLoS Med. 2005;2(10):1047.
   Web of Science ®Google Scholar
• Moran M, Guzman J, Ropars AL, et al. The role of product development partnerships in research and development for neglected diseases. Int Health. 2010;2(2):114–122.
   PubMed Web of Science ®Google Scholar
• Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med. 2011;364(6):535–541.
   PubMed Web of Science ®Google Scholar
• Wessner CW. Driving innovations across the valley of death. Res Manag. 2005 Jan 22;48(1):9–12.
   Google Scholar
• Evans DL. The advanced technology program: reform with a purpose. 2002.
   Google Scholar
• Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840–842.
   PubMed Web of Science ®Google Scholar
• Markham SK, Ward SJ, Aiman-Smith L, et al. The valley of death as context for role theory in product innovation. J Prod Innov Manag. 2010;27(3):402–417.
   Web of Science ®Google Scholar
• Germann PG, Schuhmacher A, Harrison J, et al. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective. Hum Genomics. 2013;7(1):5.
   PubMedGoogle Scholar
• Boyle LMMJBC. Transitioning to Private-Sector Financing: characteristics of Success,  Colorado USA: NREL/MP-720-31192. 2002.
   Google Scholar
• Hudson J, Khazragui HF. Into the valley of death: research to innovation. Drug Discov Today. 2013;18(13–14):610–613.
   PubMed Web of Science ®Google Scholar
• Murphy LM, Edwards PL. Bridging the valley of death: transitioning from public to private sector financing. NREL/MP-720-34036 [Internet]. Colorado (USA); 2003. [cited 2021 Apr 06]. Available from: https://www.nrel.gov/docs/gen/fy03/34036.pdf
   Google Scholar
• Coller BS, Califf RM. Traversing the valley of death: a guide to assessing prospects for translational success. Sci Transl Med. 2009;1(10):10cm9–10cm9.
   PubMed Web of Science ®Google Scholar
• Translational science and the “valley of death” [internet]. 2015 [2019 Dec 10]. Available from: https://www.openphilanthropy.org/blog/translational-science-and-valley-death
   Google Scholar
• Daniels N. How can the uk close the valley of death gap? [internet]. The Institute of Materials, Minerals and Mining. 2016 [2019 Dec 10]. Available from: https://www.iom3.org/materials-world-magazine/feature/2016/jan/05/how-can-uk-close-valley-death-gap
   Google Scholar
• López L, Vélez I, Asela C, et al. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl Trop Dis. 2018;12:7.
   Web of Science ®Google Scholar
• Omollo R, Alexander N, Edwards T, et al. Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011 Jun;12(66):1–10.
   Web of Science ®Google Scholar
• Eskandari SE, Firooz A, Nassiri-Kashani M, et al. Safety evaluation of topical application of nano-liposomal form of amphotericin B (Sinaampholeish) on healthy volunteers: phase I clinical trial. Iran J Parasitol. 2019;14(2):197–203.
   PubMed Web of Science ®Google Scholar
• Edwards T, Omollo R, Khalil EAG, et al. Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011;12(66):1–7.
   Google Scholar
• Camandaroba ELP, Reis EAG, Gonçalves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop. 2003;36(2):201–209.
   PubMedGoogle Scholar
• Veloso V, Carneiro C, Toledo M, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz. 2001;96(7):1005–1011.
   PubMed Web of Science ®Google Scholar
• Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81(5):755–759.
   PubMed Web of Science ®Google Scholar
• Alcântara LM, Ferreira TCS, Gadelha FR, et al. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int J Parasitol Drugs Drug Resist. 2018;8(3):430–439.
   PubMed Web of Science ®Google Scholar
• Chatelain E, Konar N. Translational challenges of animal models in chagas disease drug development: a review. Drug Des Devel Ther. 2015;9:4807–4823.
   PubMed Web of Science ®Google Scholar
• Romanha AJ, De Castro SL, Soeiro M de NC, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–238.
   PubMed Web of Science ®Google Scholar
• Gulin JEN. in vivo drug testing for experimental trypanosoma cruzi infection. in: Altcheh J., Freilij H, editors. birkhauser advances in infectious diseases. Cham, Switzerland: Springer, Cham; 2019. p. 313–321.
   Google Scholar
• Fonseca-Berzal C, Arán VJ, Escario JA, et al. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi. Parasitol Res. 2018;117(11):3367–3380.
   PubMed Web of Science ®Google Scholar
• Moraes CB, Franco CH. Novel drug discovery for Chagas disease. Expert Opin Drug Discov. 2016;11(5):447–455.
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Tarleton RL. Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol. 2014;7(3):317–325.
   PubMed Web of Science ®Google Scholar
• Scarim CB, Ribeiro AR, Rosa JAD, et al. Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review. Rev Soc Bras Med Trop. 2018;51(2):133–140.
   PubMed Web of Science ®Google Scholar
• Mateus J, Guerrero P, Lasso P, et al. An animal model of acute and chronic chagas disease with the reticulotropic y strain of trypanosoma cruzi that depicts the multifunctionality and dysfunctionality of t cells. Front Immunol. 2019;10:918.
   PubMed Web of Science ®Google Scholar
• De Lana M. Experimental studies of Chagas disease in animal models. In: Jenny Telleria and Michel Tibayrenc, editors. American Trypanosomiasis Chagas Disease. Elsevier; 2017. 299–320.
   Google Scholar
• Costa SCGD. Mouse as a model for Chagas disease: does mouse represent a good model for Chagas disease? Mem Inst Oswaldo Cruz. 1999;94(suppl 1):269–272.
   PubMedGoogle Scholar
• León CM, Montilla M, Vanegas R, et al. Murine models susceptibility to distinct Trypanosoma cruzi I genotypes infection. Parasitology. 2017;144(4):512–519.
   PubMed Web of Science ®Google Scholar
• Loría-Cervera EN, Andrade-Narváez FJ. Review: animal models for the study of leishmaniasis immunology. Rev Inst Med Trop Sao Paulo. 2014;56(1):1–11.
   PubMed Web of Science ®Google Scholar
• Gupta S Nishi. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res. 2011;133(1):27–39.
   PubMed Web of Science ®Google Scholar
• Mears ER, Modabber F, Don R, et al. A review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis. maes L, editor. PLoS Negl Trop Dis. 2015 Sep 3;9(9):e0003889.
   PubMed Web of Science ®Google Scholar
• Olobo JO, Gicheru MM, Anjili CO. The african green monkey model for cutaneous and visceral leishmaniasis. Trends Parasitol. 2001;17(12):588–592.
   PubMed Web of Science ®Google Scholar
• Frédéric Jean Georges Frézard, Erly Guilherme Azevedo, Raul Rio Ribeiro, Cynthia Peres Demicheli, Sydnei Magno da Silva, Simone Aparecida Rezende, inventors. Composição farmacêutica contendo lipossomas convencionais e lipossomas de circulação prolongada para o tratamento da leishmaniose visceral. BR: BR1020120052652; 2012.
   Google Scholar
• Ferdowsian HR, Beck N. Ethical and scientific considerations regarding animal testing and research. PLoS One. 2011;6(9):e24059.
   PubMed Web of Science ®Google Scholar
• Russell WMS, Burch RL. The principles of humane experimental technique [internet]. London (UK): Methuen; 1959. [cited 2021 Apr 6]. Available from: https://caat.jhsph.edu/principles/the-principles-of-humane-experimental-technique
   Google Scholar
• O’Keeffe A. Development of novel predictive 2D and 3D in vitro models for anti-leishmanial drug testing [internet]. 2018. [cited 2021 Apr 6].  Available from: http://researchonline.lshtm.ac.uk/id/eprint/4646919/
   Google Scholar
• O’Keeffe A, Hale C, Cotton JA, et al. Novel 2D and 3D assays to determine the activity of anti-leishmanial drugs. Microorganisms. 2020;8(6):831.
   Web of Science ®Google Scholar
• Haycock JW. 3D cell culture: a review of current approaches and techniques. In: John W. Haycock editor. Methods in molecular biology (Clifton, NJ). New Jersey, USA: Humana Press; 2011. p. 1–15.
   Google Scholar
• Segeritz C-P, Vallier L. Cell Culture. In: Morteza Jalali; Francesca Saldanha; Mehdi Jalali, editors. Basic Science Methods for Clinical Researchers. Cambridge, Massachusetts, USA: Elsevier; 2017. 151–172.
   Google Scholar
• Messias Sandes J, Nascimento Moura DM, Divina da Silva Santiago M, et al. The effects of endoplasmic reticulum stressors, tunicamycin and dithiothreitol on Trypanosoma cruzi. Exp Cell Res. 2019;383(2):111560.
   PubMed Web of Science ®Google Scholar
• De Souza W. Electron microscopy of trypanosomes - A historical view. Mem Inst Oswaldo Cruz. 2008;103(4):313–325.
   PubMed Web of Science ®Google Scholar
• Gadelha CAG, Temporão JG. Desenvolvimento, Inovação e Saúde: a perspectiva teórica e política do Complexo Econômico-Industrial da Saúde. Cien Saude Colet. 2018;23(6):1891–1902.
   PubMedGoogle Scholar
• Zago MF. Poder de compra estatal como instrumento de políticas públicas? In: Enap Escola (Nacional de Administração Pública), editor. Brasilia, DF, Brazil; Enap (Nacional de Administração Pública); 2018:1–466.
   Google Scholar
• Squeff FDHS. O poder de compras governamental como instrumento de desenvolvimento tecnológico: análise do caso brasileiro. Brasília (DF): Texto para; 2014.
   Google Scholar
• Fernandes DRA, Lima SML, Chagnon RP. Contribuições do modelo fatores críticos de sucesso para análise da gestão de parcerias para o desenvolvimento produtivo de um laboratório oficial. Cad Saude Publica. 2020;36(2):2.
   Google Scholar
• Lee BY, Bacon KM, Wateska AR, et al. Modeling the economic value of a Chagas’ disease therapeutic vaccine. Hum Vaccin Immunother. 2012;8(9):1293–1301.
   PubMed Web of Science ®Google Scholar